A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy

被引:93
作者
Chen, Weili
Li, Quanzhi
Hudson, Wendy A.
Kumar, Ashish
Kirchhof, Nicole
Kersey, John H.
机构
[1] Univ Minnesota, Ctr Canc, Minneapolis, MN USA
[2] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Vet Diagnost Lab, St Paul, MN 55108 USA
[4] Univ Minnesota, Canc Ctr Histopathol, St Paul, MN 55108 USA
[5] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
关键词
D O I
10.1182/blood-2005-08-3498
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The 2 most frequent human MLL hematopoietic malignancies involve either AF4 or AF9 as fusion partners; each has distinct biology but the role of the fusion partner is not clear. We produced MII-AF4 knock-in (KI) mice by homologous recombination in embryonic stem cells and compared them with MII-AF9 KI mice. Young M11-AF4 mice had lymphoid and myeloid deregulation manifest by increased lymphoid and myeloid cells in hematopoletic organs. In vitro, bone marrow cells from young mice formed unique mixed pro-B lymphold (B220(+)CD19(+)CD43(+)slgM(-), PAX5(+), TdT(+), IgH rearranged)/myeloid (CD11b/Mac1(+), c-fms(+), lysozyme(+)) colonies when grown in IL-7- and Flt3 ligand-containing media. Mixed lymphoid/myeloid hyperplasia and hematologic malignancies (most frequently B-cell lymphomas) developed in MII-AF4 mice after prolonged latency; long latency to malignancy indicates that MII-AF4-induced lymphold/myeloid deregulation alone is insufficient to produce malignancy. In contrast, young MII-AF9 mice had predominately myeloid deregulation in vivo and in vitro and developed myeloid malignancies. The early onset of distinct mixed lymphoid/myelold lineage deregulation in MII-AF4 mice shows evidence for both "instructive" and "noninstructive" roles for AF4 and AF9 as partners in MLL fusion genes. The molecular basis for "instruction" and secondary cooperating mutations can now be studied in our MII-AF4 model.
引用
收藏
页码:669 / 677
页数:9
相关论文
共 51 条
[31]   AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments [J].
Li, QZ ;
Frestedt, JL ;
Kersey, JH .
BLOOD, 1998, 92 (10) :3841-3847
[32]   LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias [J].
Ma, C ;
Staudt, LM .
BLOOD, 1996, 87 (02) :734-745
[33]   Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors [J].
Milne, TA ;
Hughes, CM ;
Lloyd, R ;
Yang, ZH ;
Rozenblatt-Rosen, O ;
Dou, YL ;
Schnepp, RW ;
Krankel, C ;
LiVolsi, VA ;
Gibbs, D ;
Hua, XX ;
Roeder, RG ;
Meyerson, M ;
Hess, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :749-754
[34]  
Morrison SJ, 1997, DEVELOPMENT, V124, P1929
[35]   Bethesda proposals for classification of lymphoid neoplasms in mice [J].
Morse, HC ;
Anver, MR ;
Fredrickson, TN ;
Haines, DC ;
Harris, AW ;
Harris, NL ;
Jaffe, ES ;
Kogan, SC ;
MacLennan, ICM ;
Pattengale, PK ;
Ward, JM .
BLOOD, 2002, 100 (01) :246-258
[36]   Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology [J].
Muyrers-Chen, I ;
Rozovskaia, T ;
Lee, N ;
Kersey, JH ;
Nakamura, T ;
Canaani, E ;
Paro, R .
ONCOGENE, 2004, 23 (53) :8639-8648
[37]   Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4:11) abnormality [J].
Rozovskaia, T ;
Feinstein, E ;
Mor, O ;
Foa, R ;
Blechman, J ;
Nakamura, T ;
Croce, CM ;
Cimino, G ;
Canaani, E .
ONCOGENE, 2001, 20 (07) :874-878
[38]  
RUBNITZ JE, 1994, BLOOD, V84, P570
[39]   General Report on the European Union Concerted Action Workshop on 11q23, London, UK, May 1997 [J].
Secker-Walker, LM .
LEUKEMIA, 1998, 12 (05) :776-778
[40]   Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9 [J].
So, CW ;
Karsunky, H ;
Wong, P ;
Weissman, IL ;
Cleary, ML .
BLOOD, 2004, 103 (08) :3192-3199